Welcome to Lymphopedia!

This site tracks all genes that have been nominated as recurrently mutated in one of the common B-cell lymphomas. Genes are categorized based on their level of support in the original primary data and other available datasets. Information for each gene can be found on their respective pages. The genes nominated by individual studies can be found on the study-centric pages.

To get started, select one of the gene lists from the table below then select the gene page link for any gene in the table or explore the genes nominated by individual studies.

Definitions

Tiers

Tier 2 Genes

Any gene described as significantly or recurrently mutated in one or more types of B-cell lymphoma is initially assigned to Tier 2 for that entity. The study describing the mutation of that gene in a particular entity is considered the originating study.

Tier 1 Genes

Genes can transition to Tier 1 only after additional studies have demonstrated the recurrence of mutations in the same entity.

Designations

aSHM

Genes documented as being affected by aberrant somatic hypermutation (aSHM) will sometimes have this designation. Tier 1 and Tier 2 genes can have this designation, depending on whether the mutation pattern has been reproduced in multiple studies.

--- config: sankey: showValues: false linkColor: target width: 750 height: 1200 nodeAlignment: right --- sankey-beta Albuquerque 2017, DLBCL Tier 1, 3 Lohr 2012, DLBCL Tier 1, 3 Lohr 2012, DLBCL Tier 2, 1 Pasqualucci 2001, DLBCL Tier 1, 2 Pasqualucci 2001, DLBCL Tier 2, 2 Mareschal 2016, DLBCL Tier 1, 2 Arthur 2018, DLBCL Tier 1, 8 Arthur 2018, DLBCL Tier 2, 12 Morin 2016, DLBCL Tier 1, 2 Morin 2013, DLBCL Tier 1, 11 Morin 2013, DLBCL Tier 2, 29 Pasqualucci 2011, DLBCL Tier 1, 2 Hubschmann 2021, DLBCL Tier 1, 3 Hubschmann 2021, DLBCL Tier 2, 20 Chapuy 2018, DLBCL Tier 1, 2 Chapuy 2018, DLBCL Tier 2, 17 Pasqualucci 2011, DLBCL Tier 1, 3 Pasqualucci 2011, DLBCL Tier 2, 4 Reddy 2017, DLBCL Tier 1, 7 Reddy 2017, DLBCL Tier 2, 53 Zhang 2013, DLBCL Tier 1, 11 Zhang 2013, DLBCL Tier 2, 8 Schmitz 2018, DLBCL Tier 1, 7 Schmitz 2018, DLBCL Tier 2, 9 Morin 2011, DLBCL Tier 1, 24 Morin 2011, DLBCL Tier 2, 1 DLBCL, DLBCL-exome, 7 DLBCL-exome, Pasqualucci 2011, 7 DLBCL, DLBCL-exome, 19 DLBCL-exome, Chapuy 2018, 19 DLBCL, DLBCL-WGS, 23 DLBCL-WGS, Hubschmann 2021, 23 DLBCL, DLBCL-WGS/exome, 2 DLBCL, DLBCL-exome, 2 DLBCL-exome, Pasqualucci 2011, 2 DLBCL, DLBCL-RNA-seq/WGS, 25 DLBCL-RNA-seq/WGS, Morin 2011, 25 DLBCL, DLBCL-exome, 19 DLBCL-exome, Zhang 2013, 19 DLBCL, DLBCL-exome, 16 DLBCL-exome, Schmitz 2018, 16 DLBCL, DLBCL-exome, 60 DLBCL-exome, Reddy 2017, 60 DLBCL, DLBCL-exome, 4 DLBCL-exome, Lohr 2012, 4 DLBCL, DLBCL-exome, 3 DLBCL-exome, Albuquerque 2017, 3 DLBCL, DLBCL-exome, 2 DLBCL-exome, Morin 2016, 2 DLBCL, DLBCL-WGS, 40 DLBCL-WGS, Morin 2013, 40 DLBCL, DLBCL-exome, 2 DLBCL-exome, Mareschal 2016, 2 DLBCL, DLBCL-WGS, 20 DLBCL-WGS, Arthur 2018, 20 DLBCL, DLBCL-Sanger, 4 DLBCL-Sanger, Pasqualucci 2001, 4 Pasqualucci 2011, FL Tier 1, 2 Hubschmann 2021, FL Tier 1, 2 Hubschmann 2021, FL Tier 2, 15 Krysiak 2017, FL Tier 1, 17 Krysiak 2017, FL Tier 2, 5 Morin 2011, FL Tier 1, 14 Morin 2011, FL Tier 2, 1 Okosun 2016, FL Tier 1, 2 Russler-germain 2023, FL Tier 1, 1 Russler-germain 2023, FL Tier 2, 19 FL, FL-WGS, 17 FL-WGS, Hubschmann 2021, 17 FL, FL-exome, 2 FL-exome, Pasqualucci 2011, 2 FL, FL-RNA-seq/WGS, 15 FL-RNA-seq/WGS, Morin 2011, 15 FL, FL-exome, 22 FL-exome, Krysiak 2017, 22 FL, FL-exome, 20 FL-exome, Russler-germain 2023, 20 FL, FL-WGS, 2 FL-WGS, Okosun 2016, 2 Muppidi 2014, BL Tier 1, 1 Muppidi 2014, BL Tier 2, 2 Panea 2019, BL Tier 1, 4 Panea 2019, BL Tier 2, 36 Thomas 2023, BL Tier 1, 2 Thomas 2023, BL Tier 2, 3 Grande 2019, BL Tier 1, 9 Grande 2019, BL Tier 2, 4 Richter 2012, BL Tier 1, 5 Burkhardt 2022, BL Tier 2, 25 Schmitz 2012, BL Tier 1, 3 Schmitz 2012, BL Tier 2, 16 Love 2012, BL Tier 1, 3 Love 2012, BL Tier 2, 56 BL, BL-RNA-seq/exome, 40 BL-RNA-seq/exome, Panea 2019, 40 BL, BL-Sanger, 3 BL-Sanger, Muppidi 2014, 3 BL, BL-WGS, 5 BL-WGS, Thomas 2023, 5 BL, BL-panel, 25 BL-panel, Burkhardt 2022, 25 BL, BL-WGS, 13 BL-WGS, Grande 2019, 13 BL, BL-RNA-seq/WGS/exome, 5 BL-RNA-seq/WGS/exome, Richter 2012, 5 BL, BL-exome, 59 BL-exome, Love 2012, 59 BL, BL-RNA-seq, 19 BL-RNA-seq, Schmitz 2012, 19 Zhang 2014, MCL Tier 1, 2 Zhang 2014, MCL Tier 2, 26 Bea 2013, MCL Tier 1, 11 Bea 2013, MCL Tier 2, 16 Nadeu 2020, MCL Tier 1, 3 Nadeu 2020, MCL Tier 2, 2 Pararajalingam 2020, MCL Tier 1, 6 Pararajalingam 2020, MCL Tier 2, 1 MCL, MCL-WGS/exome, 27 MCL-WGS/exome, Bea 2013, 27 MCL, MCL-WGS/exome, 7 MCL-WGS/exome, Pararajalingam 2020, 7 MCL, MCL-WGS, 5 MCL-WGS, Nadeu 2020, 5 MCL, MCL-exome, 28 MCL-exome, Zhang 2014, 28

Gene lists

entity Tier 1 Tier 2
Burkitt Lymphoma (BL) 29 genes 157 genes
Diffuse Large B-cell Lymphoma(DLBCL) 128 genes 198 genes
Follicular Lymphoma (FL) 66 genes 50 genes
Primary Mediastinal B-cell Lymphoma (PMBL)* 76 genes 82 genes
Mantle Cell Lymphoma (MCL) 23 genes 46 genes
Marginal Zone Lymphoma (MZL) 42 genes 74 genes

* PMBL gene list includes genes attributed to classical Hodgkin lymphoma or marginal grey-zone lymphoma

B-cell Lymphoma aSHM targets

hg19 coordinates

hg38 coordinates

Origins of B-cell lymphoma gene lists

Browse by study

B-cell lymphoma mutation browser

Gene expression distributions across B-cell lymphomas

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.